Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605489 | 0.83 | ALDH1A1 (0.43) | LMNAL3MBTL1ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL3600101 | 0.81 | PIK3CB (0.51) | LMNAHTTPIK3CAPIK3CBKMT2A | |
| SCHEMBL3596231 | 0.81 | CYP1A2 (0.38) | LMNACYP2D6CYP1A2MAPTHTT | |
| SCHEMBL3556149 | 0.80 | LMNA (0.50) | LMNABACE1ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL3600948 | 0.79 | PIK3CB (0.54) | LMNAHTTPIK3CAPIK3CBKMT2A | |
| SCHEMBL17859942 | 0.77 | CYP1A2 (0.54) | LMNAL3MBTL1ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL3938069 | 0.76 | CYP1A2 (0.49) | LMNAL3MBTL1ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL2493395 | 0.76 | CYP1A2 (0.49) | LMNAL3MBTL1ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL4892371 | 0.75 | PIK3CA (0.48) | LMNABACE1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3588014 | 0.75 | PIK3CA (0.51) | LMNAALDH1A1CYP2D6CYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| EP-2146981-A1 | PHARMACEUTICAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | LMNA 4801/4885BACE1 1366/4885L3MBTL1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.